Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AIM 001

Next Previous
Drug Profile

AIM 001

Alternative Names: AdAPT-001; AIM-001; Multi-vax TGF-beta trap transgene expressing oncolytic smart virus; TGF- Trap Adenovirus; TGF-beta trap - EpicentRx

Latest Information Update: 11 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpicentRx
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunostimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 05 Dec 2024 AIM 001 receives Fast track status from the US FDA for Soft tissue sarcoma (Combination therapy Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater)
  • 31 May 2024 Efficacy and adverse event data from the phase I/II BETA-PRIME trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 05 Apr 2024 Efficacy data from a phase II trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top